Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new immuno-oncology global collaboration to discover, develop and commercialize new antibody cancer treatments. The companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase I and plan to initiate trials in 2016 with new preclinical therapeutic candidates.     Regeneron will receive $640 million upfront, and the companies will invest $1 billion for discovery through proof of concept/Phase ...